Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : WXSH0102
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of the Efficacy and Safety of WXSH0102 in Treating VCC Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
January 13, 2025
Lead Product(s) : WXSH0102
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : CM9241GRU
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy/ Safety of Product CM9241GRU in Patients With Perennial Allergic Rhinitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 29, 2024
Lead Product(s) : CM9241GRU
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DNN.22.17.036
Therapeutic Area : Dermatology
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy/ Safety of DNN.22.17.036 in Male Patients With Pattern Hair Loss
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 10, 2024
Lead Product(s) : DNN.22.17.036
Therapeutic Area : Dermatology
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bentracimab
Therapeutic Area : Hematology
Study Phase : Phase III
Sponsor : Serb
Deal Size : Undisclosed
Deal Type : Partnership
Details : Through the acquisition, SERB has acquired exclusive US rights to the ticagrelor reversal agent PB2452 (bentracimab), a novel, monoclonal antibody fragment, from SFJ. SFJ will remain responsible for the ongoing trials of bentracimab and will work with SE...
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
November 05, 2023
Lead Product(s) : Bentracimab
Therapeutic Area : Hematology
Highest Development Status : Phase III
Sponsor : Serb
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Preclinical
Recipient : Celmatix
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to jointly investigate a novel peripherally preferred melatonin receptor agonist, discovered by Ache, for a range of women’s health indications, starting with polycystic ovary syndrome (PCOS).
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
August 08, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Preclinical
Recipient : Celmatix
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Bentracimab
Therapeutic Area : Hematology
Study Phase : Phase III
Recipient : PhaseBio Pharmaceuticals
Deal Size : $120.0 million
Deal Type : Collaboration
Details : PB2452 (bentracimab) is a novel, recombinant, human monoclonal antibody antigen-binding fragment designed to reverse the antiplatelet activity of ticagrelor in major bleeding and urgent surgery situations.
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Undisclosed
January 17, 2023
Lead Product(s) : Bentracimab
Therapeutic Area : Hematology
Highest Development Status : Phase III
Recipient : PhaseBio Pharmaceuticals
Deal Size : $120.0 million
Deal Type : Collaboration
Lead Product(s) : Bentracimab
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibody
Upfront Cash : Inapplicable
December 17, 2021
Lead Product(s) : Bentracimab
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ACH000029
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : McQuade Center
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, MSRD and Aché will collaborate to advance Aché’s novel compound ACH000029 through phase 1b clinical trials with the opportunity to expand the collaboration after those studies.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 24, 2021
Lead Product(s) : ACH000029
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : McQuade Center
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Ketorolac Trometamol
Therapeutic Area : Neurology
Study Phase : Approved FDF
Recipient : Nemera
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Nemera's multidose eye dropper Novelia® has been approved by ANVISA for the preservative-free formulations CLILON (Ketorolac 0,4% and 0,5%), a nonsteroidal anti-inflammatory drug that is used to treat moderately severe pain and inflammation, usually aft...
Product Name : Clilon
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 05, 2021
Lead Product(s) : Ketorolac Trometamol
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Nemera
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Pegcetacoplan
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase IV
Recipient : Apellis Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : In the study, EMPAVELI met the primary endpoint, demonstrating superiority to Soliris for the change from baseline in hemoglobin level at Week 16 with an adjusted mean increase of 3.84 g/dL of hemoglobin.
Product Name : Empaveli
Product Type : Peptide
Upfront Cash : Inapplicable
May 14, 2021
Lead Product(s) : Pegcetacoplan
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase IV
Recipient : Apellis Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable